Radiation therapy firm Accuray said recent research found its CyberKnife robotic radiosurgery system to be beneficial in treating central lung tumors.
Published in the January 2012 online issue of Radiotherapy & Oncology, the study results show that CyberKnife could deliver lung stereotactic body radiation therapy (SBRT) to patients with central lung lesions with minimal toxicity and high levels of tumor control, according to Accuray.
The study team, led by Dr. Joost Nuyttens, PhD, at Erasmus MC - Daniel den Hoed Cancer Center, studied 56 patients who were ineligible for surgery or chemotherapy, refused surgery or chemotherapy, or had an inoperable tumor. After treatment with CyberKnife lung SBRT, local tumor control at one year was 91% for the entire group and 76% at two years.
An analysis of toxicity rates showed no serious complications, Accuray said.
